MUC5AC and pneumonia: As a result, this reinforces that these pathways may be an identifiable component of the polygenic architecture of pneumonia that could be used to direct inhibitors of MUC5AC to patients with elevated pneumonia genetic risk amongst protein modification processes such as glycosylation.